STOCK TITAN

Third Harmonic Bio, Inc. - $THRD STOCK NEWS

Welcome to our dedicated page for Third Harmonic Bio news (Ticker: $THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Third Harmonic Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Third Harmonic Bio's position in the market.

Rhea-AI Summary
Third Harmonic Bio, Inc. appoints Dr. Geoff McDonough to its Board of Directors. Dr. McDonough brings extensive clinical and commercial experience to advance THB335 for chronic spontaneous urticaria. His background includes leadership roles at Generation Bio Co. and Sobi, with a focus on mast-cell mediated inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
management
-
Rhea-AI Summary
Third Harmonic Bio, Inc. (THRD) filed for U.S. IND for THB335 with clinical trials expected to start in 2Q’24. The company reported a strong financial position with $269.1 million in cash and cash equivalents as of December 31, 2023. R&D expenses decreased, G&A expenses increased, and net loss improved compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Summary
Third Harmonic Bio, Inc. (THRD) CEO, Natalie Holles, to participate in fireside chat at the 44th Annual TD Cowen Health Care Conference on March 5, 2024. Live audio webcast and archived replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences
Rhea-AI Summary
Third Harmonic Bio, a biopharmaceutical company focused on advancing medicine for inflammatory diseases, appoints Christopher Murphy as Chief Financial and Business Officer. Murphy brings experience from Horizon Therapeutics and JMP Securities, with a track record of translating corporate strategy into shareholder value. The company provides a business update on THB335, a KIT inhibitor for mast-cell mediated inflammatory disorders, with IND-enabling toxicology studies nearing completion and pre-IND interaction with the U.S. FDA now complete. The program remains on track to file a U.S. IND and initiate a Phase 1 study during the first half of 2024. Third Harmonic Bio maintains a strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
management
-
Rhea-AI Summary
Third Harmonic Bio, Inc. (Nasdaq: THRD) announced strong financial results for Q3 2023, with a cash position of $273.9 million, on track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24. The company continues to make progress in advancing THB335, an orally available KIT inhibitor, towards clinical trials, and believes it has the potential to be a transformative treatment for chronic spontaneous urticaria and other mast cell-driven diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Summary
Third Harmonic Bio, Inc. announces the transition of Adrian S. Ray from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. Dr. Ray will continue supporting the company's Investigational New Drug (IND) application for THB335. The company also announces the departure of Robert Ho, Chief Financial Officer, on November 10, 2023. Executive searches have been initiated for their successors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
management
Rhea-AI Summary
Third Harmonic Bio CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
Third Harmonic Bio, Inc.

Nasdaq:THRD

THRD Rankings

THRD Stock Data

486.23M
8.93M
10.01%
93.36%
1.68%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About THRD

third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. our lead product candidate, thb001, is the first highly selective, oral small-molecule kit inhibitor to enter clinical development. with promising drug-like properties and an encouraging early clinical profile, thb001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.